CD20 Antibody Primes B Lymphocytes for Type I Interferon Production

Dongsheng Xu, Andrew Staedman, Luwen Zhang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases. However, CD20 antibody failed to treat systemic lupus erythematosus (SLE or lupus). The reason for the failure is currently unknown. Type I interferons (IFN) are a major component for the host innate immunity, and a key pathogenic factor in lupus. We found that CD20 antibody potentiated human B cells for its production of IFNs in vitro. This function was specific to CD20-expressing cells and the potentiation function seems to be instant. In addition, ectopic expression of CD20 in non-B-lymphocytes increased the IFN promoter reporter activities. Because IFNs are a key pathogenic factor in lupus, our data suggest that, in the presence of virus infection, the CD20-antibody-mediated enhancement of IFN production might be related to its failure in lupus treatments. This work may provide new insights for CD20-Ab therapeutic applications.

Original languageEnglish (US)
Article numbere67900
JournalPloS one
Volume8
Issue number6
DOIs
StatePublished - Jun 18 2013

Fingerprint

Interferon Type I
Lymphocytes
interferons
B-lymphocytes
B-Lymphocytes
antibodies
Antibodies
Cells
lymphoma
Interferons
lupus erythematosus
B-Cell Lymphoma
Virus Diseases
Viruses
Innate Immunity
Systemic Lupus Erythematosus
Lymphoma
lymphocytes
viruses
therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

CD20 Antibody Primes B Lymphocytes for Type I Interferon Production. / Xu, Dongsheng; Staedman, Andrew; Zhang, Luwen.

In: PloS one, Vol. 8, No. 6, e67900, 18.06.2013.

Research output: Contribution to journalArticle

Xu, Dongsheng ; Staedman, Andrew ; Zhang, Luwen. / CD20 Antibody Primes B Lymphocytes for Type I Interferon Production. In: PloS one. 2013 ; Vol. 8, No. 6.
@article{1d35920493954a8287adac76e595acba,
title = "CD20 Antibody Primes B Lymphocytes for Type I Interferon Production",
abstract = "CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases. However, CD20 antibody failed to treat systemic lupus erythematosus (SLE or lupus). The reason for the failure is currently unknown. Type I interferons (IFN) are a major component for the host innate immunity, and a key pathogenic factor in lupus. We found that CD20 antibody potentiated human B cells for its production of IFNs in vitro. This function was specific to CD20-expressing cells and the potentiation function seems to be instant. In addition, ectopic expression of CD20 in non-B-lymphocytes increased the IFN promoter reporter activities. Because IFNs are a key pathogenic factor in lupus, our data suggest that, in the presence of virus infection, the CD20-antibody-mediated enhancement of IFN production might be related to its failure in lupus treatments. This work may provide new insights for CD20-Ab therapeutic applications.",
author = "Dongsheng Xu and Andrew Staedman and Luwen Zhang",
year = "2013",
month = "6",
day = "18",
doi = "10.1371/journal.pone.0067900",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - CD20 Antibody Primes B Lymphocytes for Type I Interferon Production

AU - Xu, Dongsheng

AU - Staedman, Andrew

AU - Zhang, Luwen

PY - 2013/6/18

Y1 - 2013/6/18

N2 - CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases. However, CD20 antibody failed to treat systemic lupus erythematosus (SLE or lupus). The reason for the failure is currently unknown. Type I interferons (IFN) are a major component for the host innate immunity, and a key pathogenic factor in lupus. We found that CD20 antibody potentiated human B cells for its production of IFNs in vitro. This function was specific to CD20-expressing cells and the potentiation function seems to be instant. In addition, ectopic expression of CD20 in non-B-lymphocytes increased the IFN promoter reporter activities. Because IFNs are a key pathogenic factor in lupus, our data suggest that, in the presence of virus infection, the CD20-antibody-mediated enhancement of IFN production might be related to its failure in lupus treatments. This work may provide new insights for CD20-Ab therapeutic applications.

AB - CD20 is a B cell surface marker that is expressed in various stages in B lymphocytes and certain lymphomas. Clinical administration of CD20 antibody, such as rituximab, is used widely to treat human B-cell lymphomas and other diseases. However, CD20 antibody failed to treat systemic lupus erythematosus (SLE or lupus). The reason for the failure is currently unknown. Type I interferons (IFN) are a major component for the host innate immunity, and a key pathogenic factor in lupus. We found that CD20 antibody potentiated human B cells for its production of IFNs in vitro. This function was specific to CD20-expressing cells and the potentiation function seems to be instant. In addition, ectopic expression of CD20 in non-B-lymphocytes increased the IFN promoter reporter activities. Because IFNs are a key pathogenic factor in lupus, our data suggest that, in the presence of virus infection, the CD20-antibody-mediated enhancement of IFN production might be related to its failure in lupus treatments. This work may provide new insights for CD20-Ab therapeutic applications.

UR - http://www.scopus.com/inward/record.url?scp=84879158239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879158239&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0067900

DO - 10.1371/journal.pone.0067900

M3 - Article

C2 - 23874371

AN - SCOPUS:84879158239

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e67900

ER -